B-cell inhibitors as therapy for rheumatoid arthritis: An update

Current Rheumatology Reports

Volumn 9, Issue 5, 2007, Pages 401-406

  Kwan Morley, Jennifer ^b   Albert, Daniel ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

CELL ACTIVATION; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DRUG HALF LIFE; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNE SYSTEM; LUPUS VULGARIS; LYMPHOMA; MONOTHERAPY; MULTIPLE SCLEROSIS; POLYARTERITIS NODOSA; POLYNEUROPATHY; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 35349007556     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0064-4     Document Type: Review

References (34)

1. Gordon DA, Hastings DE: Clinical features of rheumatoid arthritis. In Rheumatology, 3rd edn. Edited by Hochberg MC, Silman AJ, Smolen JS, et al. Philadelphia: Mosby; 2004:765-780.
2. Silman AJ, Hochberg MC: Epidemiology of the Rheumatic Diseases, 2nd edn. Edited by Silman AJ, Hochberg MC, Cooper C, et al.: Oxford: Oxford University Press; 2001:31-71.
3. Wagner UG, Kurtin PJ, Wahner A, et al.: The role of CD8+ and CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol 1998, 161:6390-6397.
4. Silverman GJ, Carson DA: Roles of B cells in rheumatoid arthritis. Arth Res Ther 2003, 5(Suppl 4):S1-S6.
5. Shaw T, Quan J, Totoritis MC: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003, 62(Suppl II):ii55-59.
6. Tan SM, Xu D, Roschke V, et al.: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003, 48:982-992.
7. Pasare C, Medzhitov R: Control of B-cell responses by Toll-like receptors. Nature 2005, 438:364-368.
8. Rifkin IR, Leadbetter EA, Busconi L, et al.: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27-42.
9. Riley JK, Sliwkowski MX: CD20: A Gene in Search of a function. Semin Oncol 2000, 27(6 Suppl 12):17-24.
10. Bubien JK, Zhou LJ, Bell PD, et al.: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993, 121:1121-1132.
11. O'Keefe TL, Williams GT, Davies SL, et al.: Mice carrying a CD20 gene disruption. Immunogenetics 1998, 48:125-132.
12. Grillo-Lopez AJ: Rituximab: an insider's historical prospective. Semin Oncol 2000, 27(6 Suppl 12):9-12.
13. Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol 1999, 26(5 Suppl 14):74-78.
14. Dorner T, Burmester GR: The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opinion Rheum 2003, 15:246-252.
15. Browning JL: B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews 2006, 5:564-576.
16. Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. This was the first randomized, double-blind, controlled study looking at the clinical response of rituximab in patients with RA.
17. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment (DANCER study). Arthritis Rheum 2006, 54:1390-1400. This phase 2b randomized, double-blind, placebo-controlled, dose-ranging trial of rituximab in RA examined the efficacy and safety of different rituximab doses plus methotrexate, with and without glucocorticoids in patients resistant to disease-modifying antirheumatic drugs.
18. Cohen SB, Emery P, Greenwald MW, et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter randomized double-blind placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 53:2793-2806. This phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluated primary efficacy and safety of rituximab at 24 weeks, along with its pharmacokinetics and pharmacodynamics.
19. Roll P, Palanichamy A, Kneitz C, et al.: Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377-2386.
20. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B Cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620. This study looked at the quantitative and phenotypic reconstitution of peripheral blood cells and its relationship to clinical response in patients with RA.
21. Leandro MJ, Cooper N, Cambridge G, et al.: Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 2007, 46:29-36.
22. Rouziere A, Kneitz C, Palanichamy A, et al.: Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 2005, 7:R714-724.
23. Vos K, Thurlings RM, Rogier M, et al.: Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:772-778.
24. Lavie F, Miceli-Richard C, Ittah M, et al.: Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007, 66:700-703.
25. Vallerskog T, Heimburger M, Gunnarsson I, et al.: Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167.
26. Cambridge G, Stohl W, Leandro MJ, et al.: Circulating levels of B lymphocyte simulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical response. Arthritis Rheum 2006, 54:723-732.
27. Genovese MC, Kaine JL, Kohen MD, et al.: Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Phase I/II ACTION study) [abstract 6]. Arthritis Rheum 2006, 54(9 Suppl):S66.
28. Manning WC, Natarajan R, Rao T, et al.: Serum BAFF levels correlate with B cell depletion in patients with rheumatoid arthritis treated with ocrelizumab [abstract 7]. Arthritis Rheum 2006, 54(9 Suppl):S67.
29. Ostergaard M, Wiell C, Sierakowski S, et al.: HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis [abstract 2122]. Arthritis Rheum 2006, 54(9 Suppl):S230.
30. Burge DJ, Shu C, Martin RW, et al.: TRU-15, a small modular immunopharmaceutical (SMIP) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis [abstract 463]. Arthritis Rheum 2006, 54(9 Suppl):S230.
31. McKay J, Chwalinska-Sadowska H, Boling E, et al.: Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BlyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum 2005, 52:S710-711.
32. Stohl W, Chatham W, Weisman M, et al.: Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BlyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 2005, 52:S444.
33. Tak PP, Thurlings RM, Dimic A, et al.: A phase IIb study to investigate atacicpet (TACI-Ig) in patients with rheumatoid arthritis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Washington, DC; November 10-15, 2006.
34. Fleischman R, Wei N, Shaw M, et al.: BR3-Fc Phase I study: safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis [abstract 461]. Arthritis Rheum 2006, 54(9 Suppl):S229.